 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The People
Executive Team
The core of the senior management team of Apitope has many years of relevant start-up and product development experience.
Keith F Martin, PhD, MRPharmS, Chief Executive Officer:
- Trained in pharmacy and neuropharmacology
- 20+ years pharmaceutical R&D and business start-up and development experience. Previous positions include:
- Founder and President of KetoCytonyx, Inc
- Global Director of Life Sciences (BTG)
- Section Head at BASF Pharma with responsibility for neuroscience research, epilepsy drug discovery and product development support
- Secured $4.6 million in seed and Series A funding for KetoCytonyx
- Directed the development of several compounds from bench to clinic in neuroprotection (KTX 0101) epilepsy (BTS 60 406, BTS 72 664, BTS 72 560), stroke (BTS 72 664), depression and psychosis (BTS 79 018)
- Key member of pre-clinical team that developed and registered Meridia (sibutramine) in USA
Prof. David Wraith, PhD, Chief Scientific Officer & Founder
- Research immunologist with 25 years experience
- 1996-2004, Head of Department of Pathology & Microbiology, University of Bristol
- Awarded research fellowships by MRC (UK), National MS Society (USA), Sidney Sussex College, Cambridge and Wellcome Trust
- Author of >100 manuscripts in peer reviewed scientific journals
- Member of research grant panels for ARC, MS Society, NIH, NKRF, and Wellcome Trust
- Member of MRC panel of experts
- Experience in bio/pharma industry
- Founder of and CSO for Apitope Technology (Bristol) Ltd.
- Member of SAB for Peptide Therapeutics, TEVA and GSK (vaccine safety advisory board)
- Expert advisor to Hoffman La Roche on autoimmune therapeutics
- Expert advisor to DTI on Stem Cell Therapies
- Expert advisor to Food Standards Agency on Peanut Allergy
Angie Jamison, Quality & Technical Director
Angie Jamison is a private consultant with a background in pharmaceutical manufacturing and quality assurance.
She specialises in QA management for smaller drug development companies especially as they prepare for their first clinical studies. Her areas of expertise include:
- Design, implementation and management of sponsors’ quality systems
- Supervision of the IMP supply chain, from audits of IDS and IMP manufacturing organisations, though project management, to release at study sites
- Preparation of CMC sections for, e.g. CTA applications
- Quality assurance audits of study sites and of clinical studies
Katie Macdonald CA, Finance Director & Company Secretary
Katie Macdonald is a senior finance professional and Chartered Accountant with 15 years’ experience, including 6 years in a senior role at a FTSE250 biotech/pharmaceutical company, followed in 2002 by the incorporation of PharmaFinance Ltd , a vehicle which provides Virtual Finance Director and Company Secretarial services to small Biotech companies.
Her experience includes:
- Vice President of R&D Finance & Administration at PowderJect Pharmaceuticals Plc.
- Preparation for IPO, and subsequent 2nd round fund raising
- Divestment of a US subsidiary company
- Post acquisition business integration of a Swedish subsidiary
In addition, Apitope has contracted with Oxford Therapeutics Consulting to provide medical advice and medical monitor services. The services are performed by the company’s chief executive, Dr Jan Steiner.
Dr Jan Steiner has a background in clinical pharmacology and clinical development in both blue chip and start up pharmaceutical companies.
- Accredited clinical pharmacologist with 25 years’ experience in the pharmaceutical industry
- Founded Oxford Therapeutics Consulting in 1992. Projects have included cancer vaccines and chemotherapeutics, immunomodulators in respiratory and CNS diseases and infectious disease vaccines
- European Medical Director for Gensia Inc
- Head of clinical pharmacology departments for Hoffman La Roche (UK) and Searle
- Has contributed to numerous successful regulatory filings to perform clinical trials in Europe and USA.
- Over 20 new entities taken into man for the first time
- Examiner for the Faculty of Pharmaceutical Medicine (Dip Pharm Med) for 18 years.
Board of Directors
Richard Daniels, Chairman
Mr Daniels is Head of the Richard Daniels Group of companies and has over 45 years of experience in the building industry and is currently on the Board of Directors of several companies.
The Richard Daniels Group has grown into property development building houses, factories, shops, supermarkets, doctors’ surgeries and has employed up to 200 people.
Richard’s skills have developed by hands on management of the business based on setting and delivering absolute precise objectives of all the undertakings he has been involved with over the years.
Dr Keith F Martin, Chief Executive Officer:
See biography under Executive Team
Prof. David Wraith, PhD, Chief Scientific Officer & Founder
See biography under Executive Team
Dr Geoffrey Vernon, Non Executive Director
Geoffrey has over twenty years experience in healthcare. His operational experience was gained with Ciba-Geigy Pharmaceuticals, Schering Chemicals Ltd and Travenol Laboratories Ltd and in fund management in the City with Rothschild’s and Advent. During the past decade Geoffrey has established a successful track record in the role of Chairman or NED during his association with more than 28 healthcare companies in France, Germany, Austria, Ireland, the UK and the USA. In the case of both Oxford GlycoSciences and MorphoSys he made a significant contribution to the growth of the companies, where valuations increased significantly via flotations on the LSE and Neur Markt respectively to in excess of $1 billion.
Geoffrey is currently Chairman of two UK quoted companies. He is also an NED of a number of companies based in Germany, Israel, Ireland and in the UK.
He holds B.Pharm, Ph.D., and MBA degrees and he is a member of the Royal Pharmaceutical Society of GB and a Fellow of the Institute of Directors. He has extensive international corporate governance experience in both private and public companies and in December 1999 Geoffrey was the first Director in the UK to be accredited with the professional qualification of Chartered Director. This qualification is awarded by the Institute of Directors after an in-depth assessment of the candidate’s experience at Board level.
Sharon Finch, Non Executive Director
Sharon is the founder of Medius Associates and has more than 20 years proven experience as an international pharmaceutical business development manager and consultant. She has extensive experience of identifying, creating, implementing and directing international business opportunities. Ms Finch also has experience of negotiating and drafting a wide range of agreements with both global and national pharmaceutical companies.
Previous industry experience includes business development appointments in the Wellcome Foundation Ltd (Wellcome Research and Wellcome Diagnostics); at Medeva plc and Ono Pharmaceutical Co. Ltd.
Dr Neil Bradshaw, Non Executive Director
Dr Bradshaw is currently director of the Enterprise at the University of Bristol and has a PhD in physical chemistry from the University of Manchester and an MBA from Warwick. He has many years experience working at the interface between research and industry. Dr Bradshaw has grounding in economic development and business support at regional and national level, as well as knowledge of the high technology markets in Europe, Japan and the USA.
Andy Allars is a Board observer appointed by Sulis Seedcorn Fund